|
Detection of Extended-Spectrum Beta-Lactamase Production in Clinical Isolates of Escherichia coli Based on MICs of Ceftazidime, Ceftriaxon and Cefepim
|
Mirzaee M   , Chitsaz M * , Mansouri S |
| , chitsaz@shahed.ac.ir |
|
|
Abstract: (13534 Views) |
| Background: Extended-Spectrum β-lactamases (ESBLs) are plasmid-mediated enzymes that hydrolyze the oxyimino β-lactam substance such as third-generation Cephalosporins (Ceftazidim, Ceftriaxone, Cefotaxime). Presence of ESBL-producing organisms results in decrease in efficacy of extended-spectrum Cephalosporines in treatment of serious clinical infections caused by these organisms. So the treatment options are limited and failure treatment and antibiotic resistance are the consequence of inadequate options. Materials and Methods: A total of 160 isolates of Escherichia coli were collected from clinical samples of three hospitals in Tehran. MICs for Ceftriaxone, Ceftazidim and Cefepime were determined by standard agar dilution method. A MIC above 1 mg/L to any of these three was subjected to confirmatory testing as per CLSI method. Results: Primary phenotypic tests revealed that 56.68% (n=89) of E.coli isolates produced extended-spectrum beta-lactamases. Using of clavulanic acid in confirmatory tests, ESBL production was confirmed in 96.7% (n=86) of isolates with primary positive phenotype. The presence of an ESBL was not confirmed in 3.3% (n=3) of the screen positive isolates. Conclusion: This study showed that ESBL productions in clinical isolates of E. coli in Tehran city's university hospitals were extremely high and it is suggested detection of ESBLs as routine tests in order to increase the effectiveness of treatment. |
|
| Keywords: Escherishia coli, ESBLs, Third generation Cephalosporin |
|
|
Full-Text [PDF 205 kb]
(3214 Downloads)
|
Type of Study: Original |
Subject:
Medicine
Received: 2017 | Accepted: 2017 | Published: 2017
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
